Our Mission...  
Mobley Research Center brings thirty years of clinical research excellence to the pharmaceutical and device manufacturing industries. Our mission is to continue this excellence into the foreseeable future.
Houston Health Hour
Dr. Mobley has a daily medical radio show, the Houston Health Hour, heard from 1-2 P.M. Monday through Thursday. If one would like to hear the program, it is available through the internet at KSEVRadio.com The radio show is a great help in enrolling subjects into clinical trials.


Experience / Curriculum Vitae

Dr. David Mobley - President & Lead Principal Investigator
(Download CV)

DAVID F. MOBLEY, M.D.
915 Gessner Suite 725
HOUSTON TX 77024-2414

BIRTHPLACE: San Francisco, CA.
BIRTHDATE: November 20, 1942

SOCIAL: Married, four children

ACADEMIC BACKGROUND:

University of Arizona, B.A. in Chemistry 1960-1965
Arizona State University (summers) 1963-1965
University of Tennessee M.D. 1965-1968

PRESENT HOSPITAL POSITIONS:
Department of Surgery, Memorial Hermann Memorial City
Attending Urologic Surgeon:
Memorial Hermann Memorial City Hospital
Spring Branch Memorial Hospital
Memorial Hermann Katy Hospital

CERTIFICATION:

American Board of Urology 1980

PAST PROFESSIONAL POSITIONS:

Teaching Assistant; Department of Pathology, University of
Tennessee Medical School. 1967-1968

Internship: University of Tennessee, Memphis. 1969-1970
Surgery Residency: Baylor College of Medicine 1970-1971
Urology Residency: Baylor College of Medicine 1973-1977

MILITARY SERVICE:

United States Air force: Major, MC. 1971-1973

HONORS AND AWARDS:

Outstanding Urologic Research Award
Baylor College of Medicine 1974
1975
First Place Award:Resident Essay Competition
South Central Section
American Urological Association 1976

First Place Award: Texas Chapter American
College of Surgeons 1977

Cullen Award for Urologic Research
Baylor College of Medicine 1977

Second Place Award: Western Section,
American Urological Association 1979


American Medical Association. 1977
Physicians Recognition Award. 1978
1980
1981
1982
1984
1987
1990
1993
1998
2000

PROFESSIONAL ASSOCIATIONS:

Harris County Medical Society

Texas Medical Association

Fellow, American College of Surgeons

Fellow, Interamerican College of Physicians and Surgeons Mobley

Fellow, American College of Emergency Physicians

American Urological Association

South Central Section, American Urological Association

American Fertility Society

American Society of Andrology

American Society of Undersea Medicine

American Society for Lasers in Medicine and Surgery

Endourological Society

Texas Medical Foundation-Peer Review Organization

Corresponding Member-Academia Peruana Cirugia

OTHER PROFESSIONAL POSITIONS:

Executive Director; The Impotence Foundation
Santa Barbara, California 1989-

Host/Moderator: Health Talk Houston, Medical Television Show
1989-1992

Executive Director: The Incontinence Foundation.
Goleta, California 1989-1992

Director: Center for Overcoming Impotence
Memorial City Medical Center, Houston 1985-

Host-Houston Health Hour-KSEV Radio
Houston 1992-

Regional Medical Director: Impotence Institute of
America; Washington D.C. 1992-1996

Consultant, American Foundation for Urologic Research
Baltimore MD 1993-


Board of Trustees, Memorial Foundation
Houston Texas
1994-

Board of Advisors-Managed Care in Urology
Published by Bard In.
1995-

UNITED STATES PATENT:

Patent number 4043346
August 23, 1977
Urethral Catheter. Developed with Dr. Neil Baum and Baylor College
of Medicine.

OFFICES HELD AND COMMITTEE APPOINTMENTS:

Population Program Action Committee
Baylor College of Medicine 1975-77

Credentials Committee, Memorial City Medical 1978-1979
Center 1981-1982
1989-1990

Emergency Committee, Memorial City Medical 1980-1981
Center 1988-1990
1991

Chairman, Emergency Committee, Memorial 1983
City Medical Center 1985

Chief, Urology Section, Department of Surgery,
Memorial City Medical Center 1981
1983
1985
1990
1993
Vice-President Medical Staff, Memorial City
Medical Center 1988

President-Elect, Medical Staff, Memorial
City Medical Center 1991

President, Medical Staff, Memorial City
Medical Center, Houston TX 1992

Memorial City Medical Center, Disaster Team 1990
1991
1992
Medical records Committee, Memorial City Medical
Center, Houston TX 1991

Chairman, Bylaws Committee, Memorial Hospital
Memorial City, Houston TX 1994

Investigational Research Review Board, Memorial Hermann Healthcare
Hospital System
Houston TX 1995-present

Chairman, Department of Surgery, Memorial Hospital, Memorial City
Houston TX 1998

Editorial Board: Journal of Men’s Health 2000-

RESEARCH:

1. Principal Investigator;"A Multicenter Comparison of the Safety and
Efficacy of Lomefloxacin vs. Ofloxacin in the treatment of Bacterial Prostatitis Protocol #S69-91-02-196
G.D. Searle & Co.

2. Principal Investigator;"A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Investigate the Long-Term Effects of Finasterde (MK- 906) in Patients with Benign Prostatic Hyperplasia." Protocol 048- 04/GHBA-909 - Merck Research Laboratories/G.H. Besselaar Associates.

3. Principal Investigator;"A Phase II Dose Ranging Efficacy Study of Oral Zanoterone, A New Steroidal Androgen Receptor Antagonist, In Men with Symptomatic Benign Prostatic Hyperplasia" Protocol #49596-005- Sterling Drug Co.

4. Principal Investigator; " A Phase II dose Ranging Safety and Efficacy Study of Oral Zanoterone in Subjects with Stage D2 Carcinoma of the Prostate," Protocol #49596-204 - Theradex/Sterling Winthrop Pharmaceuticals.

5. Principal Investigator;"Doxazosin vs. Placebo in the management of symptomatic B.P.H." A double-blind placebo-controlled long term study with a long-term open label branch. Pfizer Inc.

6. Principal Investigator; "A One-Year, Multicenter, double-Blind Comparison of the effects of SKF 105657 vs. Placebo in the treatment of symptomatic B.P.H. With Six Month Untreated Follow-Up," Protocol 105657/018 - Smith Kline Beecham Pharmaceuticals.

7. Principal Investigator;"A Randomized Double-Blind Placebo-Controlled Parallel Study to Assess the Efficacy and Safety of Four Dose Levels of RS-15385 in Men with Erectile Disorder." Protocol #92CE28-0606 - Syntex Development Corp.

8. Principal Investigator; "A Twenty-Six Week , Double-Blind, Placebo- Controlled Parallel Study With an Open-Label Extension Using Doxazosin Tablets for the Treatment of Benign Prostatic Hyperplasia," Protocol #92CE28-0606 -Pfizer Central Research, Inc.

9. Principal Investigator; "A Randomized Pilot Study to Assess the Efficacy and Safety of Two Oral Dose Levels of Delaquamine HCl in Men With Erectile Disorder.." Protocol #DELS2282-Syntex Development Research.

10. Principal Investigator; "A Phase II Dose Finding Placebo Controlled Study of Four Dose Levels of YM617 in Patients with Signs and Symptoms of Benign Prostatic Hyperplasia." Protocol #YM617US90-01 - Yamanouchi Pharmaceutical Company L\, Ltd./Oxford Research International Corporation.

11. Principal Investigator; "Ro 23-6240 (Fleroxacin) in Uncomplicated Urinary Infections in Women.A Randomized, double Blind, Prospective Study Versus Ciprofloxacin" Protocol #N3606B, Hoffman-LaRoche

12. Principal Investigator; "A Sixteen-Week, Double-Blind, Placebo-Controlled Dose Response Study Using Doxazosin Tablets For the Treatment of Benign Prostatic Hyperplasia in Normotensive Patients," Protocol #90CE28-0488 Pfizer, Inc. New York.

13. Principal Investigator; "A Phase II/III Open-Label, Long-Term, Follow-up Safety Study of Oral Zanoterone in Men with Symptomatic Benign Prostatic Hyperplasia." Protocol #49496-006 - Sterling Winthrop Pharmaceuticals Research Division.

14. Principal Investigator; "A One-Year Multicenter, Double-Blind Comparison of the Effects of Once-Daily Dosing with Three Dose Levels of SK&F 105657 or Placebo in the Treatment of Symptomatic Benign Prostatic Hyperplasia with Six-Month Untreated Follow-up," Protocol # 15385S2280 Syntex Development Research.

15. Principal Investigator; "A Two-Year, Open-Label, Multicenter Study of Oral Epristeride 80mg.Once Daily in the Treatment of Benign Prostatic Hyperplasia," Protocol #10560/051 - SmithKline Beecham ` Pharmaceuticals.

16. Principal Investigator; "A One-Year, Open Label, Multicenter Study of Oral Epristeride 80mg. Once Daily in the Treatment of Benign Prostatic Hyperplasia," Protocol #105657/051 - SmithKline Beecham Pharmaceuticals.

17. Principal Investigator;Part A - "Clinical Efficacy and Safety of Two Doses of Tolterodine Compared to Placebo, A Phase III Randomized, Double Blind, Multinational Study in Patients With Detrusor Over-Activity and Symptoms of Frequency, Urge Incontinence and Urgency." Part B - Long-Term Safety, Tolerability and Clinical Efficacy of Tolterodine-A phase III, Open, Multinational Study in Patients with Detrusor Over-Activity nd Symptoms of Frequency, Urge Incontinence, and Urgency." Protocol 940ATA009- 923, Pharmacia, Inc.

18. Principal Investigator; A Double-Blind, Placebo-Controlled, Dose-Ranging Clinical Evaluation of GII98745 and Finasteride in Subjects with Benign Prostatic Hyperplasia" Protocol #ARIA2001, Glaxo Wellcome, Inc.

19. Principal Investigator; "A Five-Month, double Blind, Placebo-Controlled, Randomized Multicenter Cross-Over Study of the Effects and Safety of Testosterone Transdermal System (TTD System) in Men Presenting with Sexual Dysfunction and Serum Testosterone Levels <350ng./dl/" Protocol #TT1000/002
SmithKline Beecham Pharmaceuticals/Clin Trials, Inc.

20. Principal Investigator; "A Double-Blind, Randomized, Placebo-Controlled Parallel Group, Multicenter, Flexible Dose Escalation Study to Assess the Efficacy and Safety of Sildenafil Administered as Required to Male Patients with Erectile Dysfunction" Protocol #148-103 (CBI-1171) Pfizer/Corning Bessalaar.

21. Principal Investigator; "A Double-Blind, Placebo-Controlled, dose-Ranging Clinical Evaluation of G1231818 In Subjects with Benign Prostatic Hyperplasia" Protocol #A1A2001,, Glaxo Wellcome Inc/Clin Trials Research, Inc.

22. Principal Investigator; "A Phase III Efficacy and safety Study of Three Fixed doses of Apomorphine SL Tablets Versus Placebo in the treatment of Male Erectile Dysfunction" M96-470, Tap Holdings./IBRD-Rostrum Global.

23. Principal Investigator; "The Maximum Tolerated and Minimum Effective Dose of OROS* in the Treatment of Patients with Urge or Mixed Urinary Incontinence."
C95-049-02, ALZA Corporation.

24. Principal Investigator; "A Double-Blind, Placebo-Controlled Crossover Design Study to Evaluate the Effects of Three Single Doses of a Selective Alpha-1 Adrenoreceptor Antagonis RS-100975-190 on Peak Urinary Flow Rate in Men with Benign Prostatic Hyperplasia (BPH)" S2679 - Roche
Bioscience.

25. Principal Investigator; "A Double-Blind, Placebo Controlled, Parallel, Fixed
Dose Study of Sertraline In The Management of Premature Ejaculation.
Protocol 96CE21-0702 Pfizer Pharmaceuticals

26. Principal Investigator; Prospective Study for Urethrin Implant used in the
Treatment of Urinary Incontinence. Protocl G930198. Mentor Urology

27. Principal Investigator; Evaluation of the Safety and Efficacy of MUSE plus the ACTIS Venous Flow Controller in Men with Erectile Dysfunction.
Protocol AV-01. Vivus, Inc. Menlo Park, CA

28. Principal Investigator; An Open-Label trial of Oral Phentolamine in Patients with Mild to Moderate Erectile Dysfunction. Protocol ZON 303
Zonagen, Inc. The Woodlands, Texas

29. Principal Investigator: A prospective Study of Mentor Alpha-1 Penile
Implant in Men with Organic Impotence.
Mentor Urology. Santa Barbara CA

30. Principal Investigator: A Prospective Study of the Efficacy and Reliability of the DP9010 Inflatable Penile Prosthesis. A Phase III
Study.
American Medical Systems. Minnetonka MN

31. Principal Investigator: A Phase III Efficacy and Safety Study Comparing
Escalating Doses of Apomorphine SL to 5 or 6 mg. Doses of Apomorphine SL or Placebo in the Treatment of Male Erectile
Dysfunction. Protocol Number M97-763
Tap Holdings, Inc.

32. Principal Investigator; Benign Prostatic Hyperplasia (BPH): Effectiveness
of Terazosin Therapy in Patients Treated With Finasteride.
Abbott/SCP

33. Principal Investigator: Duloxetine versus placebo in the relief of stress
incontinence. Protocol FIJ-MC-SAAW(a) Eli Lilly Inc.

34. Principal Investigator: Efficacy and Safety of Alfuzosin Once Dail Tablets at Two dosage Levels Versus Placebo In Patients With Symptomatic Benign Prostatic Hyperplasia. Protocol 2650. Synthelabo.

35. Principal Investigator: A Randomized, Double-blind Comparative trial
Of Biclutamide 150mg. Versus Placebo Each in Combination with
Castration as Second-line Therapy in Patients with Asymptomatic
Metastatic Prostate Cancer. Protocol 7054US/0007 Zeneca Pharmaceuticals.

36. Prinicpal Investigator: A Dose-Range Finding Double-Blind, Randomized, Placebo-controlled, Multicenter, Active Comparator Study to Determing the Effect of L-753099 in Postmenopausal Women with Predominately Urge Urinary Incontinence. Protocol 011-00Draft. Merck Research Laboratories.
37. Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Fixed-dose, Dose-Ranging Study to Assess the Safety and Efficacy of Daily Administration of a Single Oral Dose of YM905 in male and Female Patients with Urge Urinary Incontinence. Protocol 905-CL-006. Yamanouchi USA, Inc.

38. Principal Investigator: Long term Compliance of Oral Supplements by Oncology Outpatients in Need of Nutritional Support. Project 7081 Protocol 9912. Mead Johnson Nutritionals

39. Prinicipal Investigator: A Study on Incidence of Autoinflation with the American Medical Systems 700 Series Inflatable Penile Prosthesis.
Protocol AMS99-003. American Medical Systems.


40. Principal Investigator: A randomized, double-blind, placebo-controlled, multi-center, fixed dose, parallel group, 3-month comparison study to investigate the efficacy and safety of the phosphodiesterase Type V inhibitor BAY 38-9456 in males with erectile dysfunction and diabetes mellitus. Bayer Pharmaceutical Divison. West Haven CT

41. Principal Investigator: Double-blind, randomized, placebo-controlled, parallel group study of the efficacy and safety of darifenacin versus tolterodine in the treatment of subjects with overactive bladder. Protocol A1371001 Pfizer Pharmaceuticals, NY

42. Sub-Investigator: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing Oxybutinin Transdermal Systems versus Tolterodine Long-Acting Capsules in Patients with Overactive Bladder. Protocol O00011, Watson Pharmaceuticals. Salt Lake City UT

43. Principal Investigator: A Randomized, Placebo-Controlled, Double-Blind, Parallel Design, Phase 3 Trial of the Efficacy and safety of Alprox-TD in Male Patients with Erectile Dysfunction. Protocol No MED 2000-DDS
NexMed, Inc.

44.Principal Investigator; Protocol FIJ-MC-SBAY Long Term Monitoring of Safety in Subjects Treated with Duloxetene for Stress Urinary Incontinence. Lilly Pharmaceuticals. Indianapolis, IN.

45. Principal Investigator; Trial 526.26, A two phase, double blinded, randomized, parallel group design, multicenter study of Flomax capsules, 0.4 mg. Versus placebo in male pateints with acute urinary retention related to benign prostatic hyperplasia. Boehringer Ingelhem, Inc.

46. Principal Investigator, A 6-Week, Double-Blind, Placebo Controlled, Randomized, Parallel Group, Multicenter, Multidose Study of the Efficacy and safety of KW-7158 in Patients with Overactive Bladder Symptoms of Increased Urinary Frequency, Urgency and Urge Incontinence. Study 71580INT-001. Kyowa Pharmaceutical, Inc.

47. Principal Investigator, A Double-Blind, Rnadomized, Placebo-Controlled, Multicenter Study to Evaluate the Effect of Rofecoxib in Decreasing the Risk of Prostate Cancer. Protocol MK-0966-201. Merck, Inc.

48. Principal Investigator; A Randomized, Placebo-Controlled, Parallel Group Study of the efficacy and safety of Dutasteride 0.5 mg. Administered Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer. The REDUCE Trial. Protocol ARI4006.

49. Principal Investigator; A randomized, double-blind, parallel-group, placebo-controlled study evaluating the efficacy, safety, and reliability of 20mg vardenafil administered for 12 weeks compared to placebo in subjects with erectile dysfunction and a demonstrated successful first response to 20mg vardenafil.Study #BAY38-9456/100497. Bayer

50. Principal Investigator; A double blind, placebo controlled, randomized US/Latin America study to evaluate the effect of tolterodine prolonged release on nocturia in patients with symptoms of overactive bladder. Protocol 583E-URO-0084-037, IND#56,406. Pfizer/Pharmacia

51. Principal Investigator; A six month open label, randominzed multi-center study to evaluate the comparative efficacy and safety of oral Famvir in the episodic and suppressive treatment of recurrent genital herpes. Protocol CFAM810A US07, Novartis Pharmaceuticals.

52. Principal Investigator; A Multi-center, double-blind, Randomized, Active-Controlled Parallel Group Study to Evaluate the Lipid-altering Efficacy of MK-0767 in Patients with Type 2 Diabetes and Dyslipidemia. Protocol 034; Merck Inc.

53. Principal Investigator; A Multicenter, Open Label, Flexible Dose Study To Investigate the Use of Patterns of Viagra (sildenafil citrate) and the Ability of Investigators to Further Optimize Subject Satisfaction with Viagra Through Customized Instruction. Protocol A1481179, Pfizer, Inc.

54. Principal Investigator; A Multi-center, Double-blind, Randomized, Active Controlled Parallel Study in Patients with Type 2 Diabetes to Evaluate the Cardiac and Metabolic Effects of MK-0767. Merck Pharmaceuticals Inc.

55. Principal Investigator; Open Label Study on the Safety and Efficacy of 5 and 10 mg Vesicare in Patients with Overactive Bladder Symptoms. Protocol 905-UC-001 Yamanouchi Pharma America, Inc.

56. Principal Investigator; A Randmomized, double-blind, Multicenter, Placebo-controlled, Parallel group study to Evaluate the Efficacy and Safety of Valsartan (320mg.) and Hydrochlorthiazide (12.5 and 25mg) combined and alone, Valsartan 160 mg. and Valsartan 160 mg/Hydrochorthiazed 12.5 mg in Hypertensive Patients. Study No CVAH631C2301. Novartis Pharmaceuticals Corporation

57. Principal Investigator; Study of Duloxetine DCl in women of Different Demographic characteristics and Co-morbidities with Stress Urinary Incontinence: Evaluation of Efficacy and Safety. Protocol F1J-US-SBCD. Eli Lilly & Co.

58. Princiapl Investigator; An Open-Label stuidy to Evaluate the Efficacy and Safety of Tadalafil Aministered “On Demand” to Men of Various Populations with Erectile Dysfunction. Protocol No.: H6D-MC-LVFN(b) Lilly, ICOS LLC.

Textbook Chapter:

Mobley, D.F., and Baum, N.H.: Office Evaluation of the Impotent Man
In: Human Sexuality
Verlag-Springer (to be published early 1996)

A listing of Dr. Mobley's professional presentations and publications can be
made available on request.

David F. Mobley, M.D.

PRESENTATIONS:

1. Patch Graft Cystoplasty
South Central Section A.U.A.
San Juan, P.R.
September 27, 1975 (First Place Award)

2. In-Situ Ureteral Graft
South Central Section A.U.A.
September 27, 1975

3.. Erythromycin in Treatment of Prostatitis
Kimbrough Annual Seminar
San Antonio TX
October 5-9, 1975

4. Experimental Model for Varicocele
American Urological Association
Las Vegas NV
May 17-20, 1976

5. Replacement of a Large Segment of Ureter with Autologous
Ureteral Graft.
American College of Surgeons
Dallas, TX
October 17-21, 1977 (First Place Award)

6. Evaluation of the Impotent Male
AASECT
New Orleans, LA
November 11, 1978

7. Evaluation and Treatment of Impotence: Experience with the
Inflatable Penile Prosthesis
Southern Medical Association
Atlanta, GA
November 12, 1978

8. Evaluation and Treatment of Prostatitis
St. Mary's Medical Center
Evansville, IN
February 13, 1980

9. Treatment of Prostatitis Exhibit
Southern Medical Association
Las Vegas NV
Nov 2-5, 1979

10. Indanyl Carbenicillin in the Treatment of Chronic
Bacterial Prostatitis
Delaware Academy of Medicine
Wilmington DE
May 6, 1980

11. Prostatitis Update
St. Louis Urological Society Semi-Annual Meeting
St. Louis MO
June 12, 1980

12. Fertility and Vasectomy
Associasion Para Estudio Reproduccion Humana
Monterrey Mexico
August 10-12, 1980

13. Evaluation and Treatment of Impotence
Grayson Co. Medical Society
September 1980
Mobley

14. Evaluation and Treatment of Impotence
South Carolina Academy of Family Practice
Charlotte
November 8, 1980

15. Treatment of Chronic Prostatitis
South Carolina Academy of Family Practice
Charlotte
November 8, 1980

16. Carbenicillin in the Treatment of Prostatitis
New Orleans Urological Society
New Orleans LA
Feb 5, 1981

17. Carbenicillin vs. TMP-SMX in the Treatment of
Prostatitis
Scientific Exhibit
American Academy of Microbiology
Dallas TX
March 1, 1981

18. Carbenicillin in the Treatment of Acute and
Chronic Prostatitis
Scientific Exhibit (Second Place Award)
Western Section
American Urological Association
Salt Lake City UT
June 29-July 2, 1981

19. Prostatitis Update
Arkansas Academy of Family Practice
Little Rock AR
August 7, 1981

20. Evaluation and Treatment of Chronic Prostatitis
University of Arizona Medical Center
Tucson AZ
November 16, 1982

21. Treatment of Urinary Infections in Males
Gunderson Medical Clinic and Medical Center
LaCrosse WI
February 10, 1982

22. Chronic Prostatitis
Pennsylvania State Medical School
Hershey PA
February 15, 1982

23. Surgical Treatment of Male Impotence
Texas Psychological Association Annual Meeting
Houston TX
December 1981

24. Evaluation and Treatment of Lower Urinary Tract Infections
in Men
Tucson Association of Osteopathic Physicians
Tucson AZ
May 10, 1983

25. Applied Model for Effective Diagnosis and Treatment of Impotence
A Team Approach and Algorithm
(Presented with Avi Raphaeli, Ph.D.)
Sixth Annual World Sexology Conference
Washington DC
May 25, 1983

26. Lower Urinary Infections in Men
Washington DC Urological Society
Washington DC
October 23, 1982

27. Treatment of Prostatitis:An Update
Medical College of Wisconsin
Milwaukee WI
December 2, 1982

28. Trauma to the Urinary Tract
Houston Community College
Health Careers Education Division
May 9, 1984

29. Percutaneous Removal of Renal Calculi
Presented to Association of Surgical Technologists, Inc.
Body Human Seminar
Houston TX
September 15, 1984

30. Medical and Surgical Management of Renal Stone Disease
Memorial City Medical Center
University of Texas
Staff Seminar
September 27, 1984

31. Management of Trauma to the Urinary Tract
Houston Community College
Paramedical Training Seminar
Houston TX
October 1, 1984

32. Impotence and the Diabetic Male
Presented to Memorial City Medical Center
Diabetic Support Group
Houston TX
July 17, 1985

33. Treatment Options for Organic Impotence
Presented to Overcoming Impotence Seminar
Memorial City Medical Center
Houston TX
July 19, 1986

34. Evaluation and Treatment of Prostatitis
Presented to Family Practice Seminar
San Jacinto Methodist Hospital
Baytown TX July 28, 1986

35. Treatment of Renal Calculi
Seminar
Memorial City Medical Center
Houston TX
December 14, 1990

36. Treatment of Male Impotence
Treatment of Urinary Incontinence
Southwest Insurance Association
Regional Meeting
Houston, TX
January 22, 1991

37. Medical Management of BPH.
Presented to Memorial City Medical Center Staff
and University of Texas Health Science Center
Houston Texas
October 1, 1992

38. Non-Surgical Approaches to Benign Prostatic
Hypertrophy.
Texas Academy of Family Practice
Lufkin Texas
October 5, 1992

39. Natural History of Benign Prostatic Hypertrophy & Therapy.
Family Practice Group. Houston Texas October 17, 1992.

40. Carcinoma of the Prostate: Evaluation and Diagnosis.
Family Practice Group. Houston TX. October 17, 1992.

41. Evaluation and treatment of Diabetes-Related Impotence:
Seminar on Diabetes and Aging.
Memorial City Medical Center. Houston TX February 12, 1993.

42. Medical Management of Prostatic Disease.
Nueces County Medical Society. Corpus Christi Tx February 16, 1993

43. A Sixteen-week, Double-Blind, Placebo Controlled, Dose-Titration Study
Using Doxazosin Tablets For the Treatment of BPH in Normotensive Pts.
Presented to American Urological Association Meeting, in conjunction with
Dr. J. Gillenwater. San Antonio TX. May 1993.

44. Evaluation and Treatment of Erectile Failure: Presented to Memorial City Medical Center Medical Staff Conference. Auspices of University of Texas
Medical School at Houston. Houston TX. April 22, 1993.

45. Medical Options in the Treatment of BPH: Presented to the Alamo Chapter, Texas Academy of Family Practice.
San Antonio TX April 27, 1993.

46. Recent Advances in the Treatment of BPH : Presented to Houston Family Practice Physician Group.
Houston TX May 11, 1993.

47. Finasteride and Alpha-Blockers in the Treatment of Benign Prostatic
Hypertrophy. Presented to The Hillcroft Medical Clinic.
Houston Texas, May 26, 1993.

48. Medical Management of BPH for the Primary Care Physician
Presented to: Medical Staff; Nan Travis Memorial Hospital
Sponsored for CME Credit by TMA
Jacksonville TX May 7, 1993.

49. Early Detection of Prostate Cancer: The Role of PSA Determination
Presented to: Industry Medical Leaders as a roundtable discussion
Houston Texas May 8, 1993.

50. Medical Management of BPH and Prostate Cancer Screening.
Presented to Victoria Medical Assn.
Victoria Texas June 22, 1993.

51. Treatment Options for Benign Prostatic Hypertrophy
Presented to Seguin Medical Society
Seguin Texas July 13, 1993

52. Doxazosin: Improved Urodynamics and Symptomatology in
Normotensive BPH Patients
Presented with Jay Gillenwater, M.D.
International Prostate Symposium
Paris France, July 1993

53. Prostate Cancer, Overview.
Presented to Memorial City Medical Center
Houston Tx September 8, 1993

54. Update in the Management of Benign Disease of the Prostate
A national teleconference video
Sponsored by the National Institutes of Health
Bethesda MD
October 26, 1993

55. The Effect of Zanoterone, a Steroidal Androgen Receptor Agonist in
Men with Benign Prostatic Hypertrophy.
Presented to American Urological Association Meeting
San Francisco, CA May 15, 1994

56. Medical Management of BPH.
Presented to: Texas Academy of Family Practice, Mid-Winter Seminar
San Antonio Texas February 18, 1994

57. Evaluation and Treatment of Impotence for the Primary Care Physician
Presented to: Texas Academy of Family Practice, Mid-Winter Seminar
San Antonio Texas, February 19, 1994

58. Medical Management of BPH.
Presented to Austin Count Medical Society
Columbus TX March 15, 1994

59. BPH Intervention: Clinical Presentation, Diagnosis and Medical
Management.
Presented to Family Practice BPH Roundtable
Houston TX March 29, 1994.

60. You , Your Prostate, and Your Health
Presented to: Men's Association, St. Lukes Methodist Church
Houston TX April 11, 1994

61. Physicians on a Tightrope.
Presented to Annual Meeting Oklahoma Urological Association
Aston Oklahoma, April 16.1994.

62. The Urological Practice Under Health Care Reform
Presented to: Annual Meeting Oklahoma Urological Association
Aston OK, April 16,1994.

63. Roundtable Discussion-Management of Symptomatic and Asymptomatic
BPH Patients. For: Oklahoma Urological Association Annual Meeting.
Aston OK April 16, 1994.

64. Practical Approach to the management of BPH
Presented to Denver Family Practice Roundtable
April 19, 1994.

65. Medical Management of men with BPH
Presented to Little Rock Family Practice Seminar
Little Rock AR, April 21, 1994.

66. Prostate Cancer and You
Presented to Men's Fellowship Group
Memorial Drive Presbyterian Church
Houston TX April 24, 1994.

67. A Practical Approach to the Management of BPH
Presented to Fresno Family Practice Symposium
Fresno CA April 27, 1994

68. Medical Management of Benign Prostatic Hyperplasia
Presented to Wichita Family Practice Symposium
Wichita KS May19,1994

69. Proscar and Your Prostate Health
Presented to Advanced Proscar Study Group
Houston TX May 21, 1994.

70. Doxazosin in the Management of Symptomatic BPH. Results with 566
Results with 566 Patients.
Presented to the Annual Meeting American Urological Association
San Francisco CA May 16, 1994

71 Medical Management of BPH
Presented to Family Practice Seminar
Wichita KS May 24, 1994

72. Proscar in the Management of BPH
Presented to Primary Care Symposium
Lubbock TX May 26, 1994

73. Medical Management of Symptomatic BPH
Presented to Family Practice Symposium
El Dorado KS June 1, 1994

74. Proscar and Alpha-Blockers in the Management of BPH
Presented to The Family Clinic
Hutchinson KS, June 7, 1994

75. Evaluation and Treatment of Symptomatic BPH
Presented to: Family Practice Symposium
Dilly, TX June 9, 1994

76. Practical Approach to the Diagnosis and Management of Symptomatic
BPH: A Urologists Perspective.
Presented to Primary Care Physicians of Berwin
Berwin Il, June 16, 1994

77. Finasteride and Alpha Blockers in the Management of BPH
Presented to Family Clinic
New Iberia La, June 21,1994

78. A Non Surgical Approach to Management of BPH in the Symptomatic Male
Presented to: Primary Care Symposium
Fort Worth, TX, June 23, 1994

79. Results of United States Studies of the Efficacy of Doxazoasin in the
Management of BPH.
Presented to Investigator's Meeting, Pfizer Pharmaceutical Research
West Palm Beach Fl, June 25, 1994

80. Alpha Blockers and Finasteride in the Management of BPH
Presented to: Brenham Clinic Foundation
Brenham TX June 28, 1994

81. A Practical Approach to the Management of Symptomatic BPH
Presented to: Primary Care Physicians Clinic
Indianapolis, IN June 30, 1994

82. Evaluation and Practical Management of BPH
Presented to The Family Medicine Roundtable
Tyler TX July 21, 1994

83. How We Work-Up the Man with BPH
Presented to Nueces County Pharmaceutical Assn.
Corpus Christi TX July 24,1994

84. Practical Management of BPH for the Primary Care Physician
Presented to the Family Care Roundtable
New Orleans LA July 27, 1994

85. Urologic Management of BPH.
Presented to Family Practice Symposium
Indianapolis IN August 4, 1994

86. The Evaluation and treatment of BPH for the Primary Care Physician
Presented to the Texas Academy ofd Philippine Physicians
Houston TX August 6, 1994

87. Primary Care-Symposium-How I Manage the BPH Patient
Presented to Medical Care Symposium
New Orleans LA, August 9, 1994

88. Management of Impotence in Diabetes Mellitus
Presented to Diabetes Focus Symposium
Memorial Hospital, Memorial City
Houston TX August 13, 1994

89. Medical Management of BPH
Presented to Primary Care Symposium
Chicago IL July 12, 1994

90. A Practical Approach to the Management of Benign Prostatic Hyperplasia
Presented to New Iberia Parish Medical Society
New Iberia La August 30, 1994

91. BPH and the Primary Care Physician
Presented to Family Practice Medical
Santana KS August 31, 1994

92. Terazosin and Finasteride in the Treatment of BPH
Presented to Family Practice Symposium
Sioux Falls SD September 1, 1994
Mobley
93. Urology in the Upcoming Healthcare Reform Environment
Presented to South Oklahoma Urological Society
Oklahoma City OK September 7, 1994

94. Medical Management of BPH
Presented to Medical Staff Meeting
Northwest Medical Center
Houston TX September 13, 1993

95. Medical Management of BPH
Presented to Primary Care Roundtable
Camden TN September 14, 1994

96. A Practical Approach to Medical and Surgical Treatment of BPH
Presented to Family Practice Symposium
San Antonio TX October 14, 1994

97. The Urologist's Future in the Management of BPH
Presented to Urology Resident's Seminar
St. Louis University
St. Louis MO. October 26,1994

98. Medical Management of BPH
Presented to Family Practice Seminar
Lake Jackson TX October 27, 1994

99. Common Urologic Problems in Family Practice
Presented to Staff Meeting, Sweeny Community Hospital
Sweeny TX November 3, 1994

100. Medical Management of BPH
Presented to Bi-Parish Medical Society
Lafayette LA Nov. 5, 1994

101. A Practical Approach to the Diagnosis and Treatment of BPH
Presented to Family Practice Roundtable
New Orleans LA Nov. 6, 1994

102. Health Care Reform and Urology
Presented to Urologic Roundtable
Minneapolis MN Nov. 8, 1994

103. Making the Public Aware of Prostate Disease Mobley
Presented to Urologic Roundtable
Minneapolis MN Nov. 8, 1994

104. Impact of Health Care Reform on the Practice of Urology
Presented to Colorado Urological Symposium
Vail CO DEC 3, 1994

105. Urological Perspective on BPH and the Primary Care Physician
Presented to Colorado Urological Symposium
Vail CO Dec 3, 1994

106. Practical Medical Management of BPH
Presented to Parish Medical Society Monthly Meeting
Monroe LA Dec 8, 1994

107 Medical Management of BPH
Presented to Family Practice Roundtable
Tuscaloosa AL Dec 20, 1994

108. Medical Management of BPH for the Primary Care Physician
Presented to Medical Staff Meeting
Family Practice
Seguin TX March 17, 1995

109 Alpha Blockers and Finasteride in the Treatment of BPH
Primary Care Symposium
Kearny NE March 21, 1995

110. Management of BPH for the Primary Care Physician
Primary Care Roundtable/Lecture
St. Louis MO March 30, 1995

111. All About Your Prostate Health
Presented to: Conoco Oil Co. Executive Staff
Houston TX April 17, 1995

112. Safety of Doxazosin in the Treatment of BPH
Presented to: Annual Meeting, American Urological Assn.
Las Vegas NV April 24, 1995

113. Management of BPH for the Primary Care Physician
Presented to: Primary Care Symposium
San Antonio TX May 1, 1995

114. Medical Management of BPH
Presented to Medical Staff CME Meeting
Memorial Hospital Memorial City
Houston TX June 1, 1995

115. Evaluation and Management of Male Erectile Dysfunction
Marketing Your Impotence Practice
Office Efficiency-Tips and Ideas
Presented to Urologic Roundtable
Mentor Corporation
Minneapolis MN June 10, 1995

116. Evaluation and Medical Management of BPH
Presented to Family Care Symposium
New Braunfels TX June 15, 1995

117. Doxazosin in the Management of Benign Prostatic Hyperplasia
Presented to 3rd. International Consultation on BPH
Monaco, June 27, 1995

118. Medical Management of BPH for the Primary Care Physician
Presented to Hitchcock Clinic
Keen NH, August 4, 1995

119. Medical Management of BPH for the Primary Care Physician
Presented to family practice roundtable
Fort Worth TX August 18, 1995.

120 Management of Impotence, All Aspects of the Condition.
Managed Care-The Effect on Urology
Increasing Efficiency in the Office Environment
Presented to Urologists Forum
Minneapolis MN August 26, 1995

121. Alpha Blockers in BPH and Hypertension
Presented to Cardiology Roundtable
Houston TX

122. Medical Management of Benign Prostatic Hyperplasia
Presented to: Physicians Roundtable
Galveston TX September 5, 1995

123. BPH, Past, Present and Future:
Presented to South Central Section, American Urological Association
Annual Meeting
Kansas City MO September 10, 1995

124. Management of Impotence
Managed Care-the Impact on Urology
Increasing Efficiency in the Office
Presented to Urology Roundtable
Minneapolis MN September 16, 1995


125. Medical Management of Benign Prostatic Hyperplasia
Moderator of Symposium
Speaker
Presented to primary care symposium/The PROTECT system
Broken Arrow OK Sept 21, 1995.

126. Medical Management of Benign Prostatic Hyperplasia
Presented to Primary Care Roundtable Symposium
College Station TX September 29, 1995.

127. Management of BPH for the Primary Care Physician
Presented to: Payne county Medical Society Educational Seminar
Stillwater OK October 3, 1995

128. Medical Management of BPH-Nuances of Apha Blocker Therapy
Presented to: Family Practice Symposium
Victoria TX October 5, 1995.

129. Medical Management of BPH for the Primary Care Physician
Presented to Family Medicine Seminar
Houston TX October 9, 1995

130. Evaluation and Management of the Impotent Male
Evaluation and Management of BPH
Presented to Our Lady of the Lake Hospital Staff
Baton Rouge LA October 12, 1995

131. Developing your Referral Practice: The Urologic Practitioner
Presented to Urology Symposium
Portland Oregon October 25, 1995.

132. BPH for the Primary Care Physician
Presented to Carlson Family Clinic
Portland Oregon, October 26, 1995

133. Managing Urology in the New Healthcare Environment
Presented to Urology Colloquium
Seattle WA, October 26, 1995

134. Medical Treatment of Benign Prostatic Hyperplasia
Presented to Family Practice Symposium (teleconference)
Flint MI October 30, 1995

135. Evaluation and Medical Therapy for BPH
Presented to Primary Care Seminar
Brenham TX October 30, 1995

136. Evaluation and Treatment of BPH
Presented to Brazoria County Medical Society Monthly Meeting
Lake Jackson TX Nov 2, 1995

137. My Experience in Talk Radio-What Your Patient Never Tells You
Presented to Men's Health Symposium
University of Texas Medical Branch-Galveston TX
November 4, 1995

138. Managed Care and the Urology Practice in the 90's
Presented to Urology Seminar
Minneapolis MN Nov. 10, 1996

139. Surgical Management of the Impotent Patient
Marketing Your Urology Practice
Presented to Urology Seminar
Minneapolis MN Nov. 11, 1995

140. Medical Management of BPH
Presented to Protect System BPH Seminar
Boise Idaho, November 16, 1995

141. Medical Management of BPH
Presented to Family Practice Symposium
Palacios TX
November 27, 1995

142. Educating the Primary Physician on Evaluation and Treatment of BPH Patients
Nuances of Newer Therapies for BPH
Presented to Annual Kibrough Urological Seminar
Washington DC. November 30, 1995

143. BPH-A Urologists' Perspective
Presented to Mid-Winter Medical Symposium
Breceknridge CO November 9, 1995

144. Medical Management of BPH for the Primary Care Physician
Presented to Family Care Seminar
New Orleans LA November 11, 1995.

145. Challenge of Impotence in the Urology Practice
Presented to: Annual Sales Meeting, Pfizer-American Medical Systems
San Diego CA. January 19, 1996

146. The Challenges of Urology in the 90's
Presented to Merck Pharmaceuticals Sales Force Meeting
Aspen CO Jan 25, 1996

147. BPH and the Family Physician
Presented to Primary Care Symposium
Victoria TX February 5, 1996

148. Medical Management and Economic Issues Regarding BPH
Presented to Salina Medical Society Meeting
Salina KS April 9, 1996


149. Results of Finasteride Studies
Presented to Urology Roundtable
Miami FL April 11, 1996

150. Urologic Economics in 1996.
Presented to Oklahoma State Urological Assn. Annual Meeting
Oklahoma City OK April 13, 1996

151. Challenges for the Urologist in the 1990's
Presented to Urology Roundtable Seminar
Houston TX April 24, 1996

152. Management of BPH for the Primary Care Physician
Presented to Houston Family Practice Update Seminar
Houston TX April 30, 1996

153. Results of Finasteride Long-Term Studies
Presented to Urology Seminar
Orlando Fl May 7, 1996

154. Doxazosin in Patients with BPH: Effects as a Function of
Baseline Disease Severity.
Presented to Annual Meeting American Urological Association
Orlando FL. May 7, 1996

155. Diabetes and Impotence
Presented to Diabetes Focus Seminar
Memorial Hospital, Memorial City
Houston TX May 11, 1996

156. Economic Considerations in the Management of BPH
Spokane Urological Colloquium
Coeur d"Alene, ID May 21, 1996

157. Benign Prostatic Hyperplasia Intervention: What are the Alternatives?
Kootenai Medical Center
Coeur d"Alene ID May 22, 1996

158. How do Urologists Choose BPH Therapy?
Eastern Washington School of Pharmacy
Spokane WA May 22, 1996

159. Health Care Reform and its Impact on Urology
Presented to Urology Roundtable
Minneapolis MN June 7, 1996

160. Marketing Your Urology Practice for Impotence
The Effective Management of the Urology Office
Presented to Urology Roundtable
Minneapolis MN June 8, 1996

161. Is Your Physician Answering All Your Questions?
Presented to the "Over 55 Seminar"
Houston TX June 10, 1996

162. Long-Term Disease Management-The Results of Finastreride Studies
Presented to Urological Roundtable
Lynchburg VA June 12, 1996

163. Case Studies in BPH and Male Impotence
Presented to Medical Society Colloquium
Muskogee OK June 25, 1996

164. Long-Term Disease Management-the Results of Finasteride Studies
Presented to Urology Roundtable
Houston TX June 26, 1996

165. The Challenges of Urology in the Upcoming Decade
Presented to: San Antonio Urology Associates
San Antonio TX. July 8, 1996.

166. Meta-Analysis of Finasteride Studies
Presented to
July 10, 1996

167. The Math of Health Care Reform
Presented to Urology Roundtable
Minneapolis MN June 12, 1996

168. Marketing for the Impotent Patient
Presented to Urology Roundtable
Minneapolis MN June 13, 1996

169. BPH Case Presentations
Presented to combined Primary Care/Urology Symposium
Phoenix AZ July 22, 1996

170. Management of BPH for the Primary Care Physician
Presented to Holt-Krock Medical Seminar
Fort smith AR July 27, 1996

171. 26-Week Efficacy and Safety of Doxazosin in the Treatment of
Benign Prostatic Hyperplasia
Presented to: European Association of Urology Annual Meeting
Paris France Sept 1, 1996

172. Case Studies in BPH
Presented to Urology-Primary Care Symposium
Denver CO Oct 6, 1996

173. Update on Finasteride Studies
Presented to Urology Roundtable
Pocatello Idaho October 10, 1996

174. Urology at the end of the 90's-Preparing for the Future
Presented to Urology Roundtable
Oakland CA November 2, 1996

175. Update on Finasteride Studies-Summary Reviews
Presented to Urology Roundtable
Bainbridge GA, November 5, 1996

176. Making the Most of Your Physician Visit
Presented to the Windsor Club
Houston TX November 6, 1996

177. Disease Management-Update on Finasteride Studies
Presented to Family Practice/Urology Roundtable
Tucson AZ November 19, 1996

178. Prostate Disease and the Primary Care Physician
Presented to Knapp Medical Center
McAllen TX November 22, 2996

179. Choosing the “Best” Therapy for BPH
Presented to Medical/Urological Symposium
Houston TX Mar 24, 1997

180. Early Detection and Treatment of Prostate Cancer
Presented to Over 55 Seminar
Houston TX Mar 31, 1997

181. The Results of the Finasteride Meta-Analysis
Presented to Urological Society Meeting
El Paso TX March 25, 1997

182. How to Improve Your Physician-Patient Relationship
Presented to the Memorial Foundation
May 11, 1997

183. The Impact of Managed Care on the Urology Practice
Presented to Urology Colloquim
Minneapolis MN May 30, 1997

184. External Marketing in Today’s Environment
Presented to Urology Colloquium
Minneapolis MN May 31, 1997

185. Internal Marketing for the Impotence Practice
Presented to Urology Colloquium
Minneapolis MN May 31, 1997

186. Evaluation and Treatment of Erectile Dysfunction
Presented to The Heart Institute
Port St. Lucie, FL, June 17, 1997

187. Interstitial Cystitis-Program Chair
Houston TX June 19, 1997

188. Impotence, Causes, Evaluation and Management
Presented to Impotence Seminar Group
Houston TX July 1, 1997

189. Choosing the Best Therapy for BPH
Presented to Good Shepherd Medical Clinic
Longview TX August 11, 1997

190. Screening and Diagnosis of Erectile Dysfunction
Presented to BPH and Other Urologic Disorders
Symposium
Houston TX August 16, 1997

191. 1. External Marketing in the Urology Practice

192. 2. Internal Marketing in the Urology Practice.
Presented to Urology Roundtable
Minneapolis MN August 23, 1997

193. Visiting Professorship: Techniques Of Penile Implant Surgery
Hospital Provincial, Oviedo Spain. September 15, 1997

194. Visiting Professorship: Techniques of Penile Implant Surgery
Lecture in Pre and Post-operative Care
Hospital Carlos Alla Malaga Spain, September 16, 1997

195. Visiting Professorship/Urology: Techniques of Infrapubic vs.
Penoscrotal Approach in Penile Prosthesis Surgery
Hospital Universario de Granada
Granada Spain September 17, 1997

196. Visiting Professorship/Urology: Techniques in Management of
Post Infection Implant Surgery.
Hospital Universario del Rio Herrero Valladolid Spain September 18, 1997

198. Choosing the “Best” Therapy for BPH
Presented to Wilford Hall USAF Hospital Urology Staff
San Antonio TX Sept 29, 1997

199. Prostate Cancer-What are the Options?
Presented to Memorial 55+ Meeting
Houston TX October 15, 1997

200. BPH-Choosing the Best Treatment Options
Presented to Urology Seminar
Houston TX October 16, 1997

201. External Marketing in the Urology Profession
Presented to Urology Marketing Seminar
Coral Gables FL October 25, 1997

202. Recent Data on Medical Management of BPH and End-Point Analysis
Presented to The Urology Group
Cincinnati Ohio. October 27, 1997

203. Visiting Professorship; Hospital General De Jerez. Teaching Penile
Prosthesis Surgery and Lecturing on Trouble-Shooting Penile Implant
Surgery. Jerez Spain, November 3, 1997

204. Visiting Professorship; Hospital General de Albacete;. Teaching Penile
Prosthesis Surgery; Lecture: Complications of Implant Surgery.
Albacete, Spain. November 4, 1997

205. Visiting Professorship; Hotel Doce de Octubre, Madrid Spain.
Teaching Penile Prosthesis Surgery; Lecture: Avoiding and Manageing
Penile Prosthesis Problems. November 5, 1997

206. Visiting Professorship; Hospital Virgen del Mar. Madrid Spain. Surgical
Management of the Difficult Implant Patient. Treatment of Severe
Fibrosis. Madrid Spain. November 6, 1997

207. External Marketing in the Urology Practice: Presented to Urology
Seminar. Tucson AZ Feb 28, 1998.

208. Internal Marketing in the Urology Practice: Presented to Urology
Seminar. Tucson AZ Feb 28, 1998.

209. Results of the PLESS study. Presented to Primary Care Seminar.
Minneapolis, MN March 17, 1998

210. Internal Marketing in the Urology Practice for the year 2000. Presented to Urology conference. Miami Florida, March 21, 1998

211. Dealing with the Impotent Patient in the Practice Setting. A roundtable presentation. Presented to Urology Conference, Miami, Fl March 21, 1998

212. The Surgical Management of Benign Prostatic Hyperplasia. Presented to
Videoconference sponsored by the Southern Medical Assn. Birmingham AL 4-7-98

213. A Urologist’s Perspective on the Management of Erectile Dysfunction. Presented to Pfizer Scientific Forum. The Houstonian, Houston TX
4-13-98.

214. Results of the VA Co-Operative Study in the Treatment of BPH
Presented to Primary Care Roundtable. Houston TX 4-18-98

215. Results of the PLESS Study. Presented as teleconference nationwide. April 13, 1998.

216. Results of the PLESS Study. Prsented as teleconference nationwide. April 15, 1998

217. Results of the PLESS Study. Prsented as teleconference nationwide. April 16, 1998

218. Results of the PLESS Study. Prsented as teleconference nationwide. April 17, 1998

219. Results of the VA Co-operative study comparing terazosin, finasteride and combination therapy in the treatment of BPH. Presented to Primary Care
Seminar. Houston TX April 18, 1998

220. The Workup of the Impotent Patient. Presented to Texas Urological Society Annual Meeting. Puerto Vallarta Mexico April 30, 1998.

221. Treatment of the Impotent Patient. . Presented to Texas Urological Society Annual Meeting. Puerto Vallarta Mexico May 1, 1998.

222. Keynote Address: Your Prostate and Your Potency. Presented to the Health and Fitness Expo. Houston Texas, May 2, 1998

223. Urologic Manifestations of Diabetes. Presented to Diabetes Focus Seminar. Houston TX May 9, 1998

224. Evaluation and Treatment of Male ED. Teleconference Presentation. Houston TX May 12, 1998

225. Evaluation and Treatment of Male ED. Presented to Primary Care Seminar. Houston TX May 13, 1998

226. Evaluation and Treatment of Male ED. Presented to Primary Care Seminar. Houston TX May 14, 1998

227. Results of the PLESS Study. Presented to Wisconsin Urological Society annual Meeting. Milwaukee WI. May 17. 1998

227. Evaluation and Treatment of Male ED. Presented to CME Grand Rounds. Memorial Hospital Houston TX May 21, 1998

228. Office Evaluation of the Impotent Man. Presented to the Medical Clinic of Houston. June 2, 1998. Houston TX

229. Results of the PLESS Study-Incidence of Acute Urinary Retention and BPH-related surgery. A Teleconference Presentation. June 18, 1998. Houston, TX

230. Results of the PLESS Study-Incidence of Acute Urinary Retention and BPH-related surgery. A Teleconference Presentation. June 18, 1998. Houston, TX

231. Results of the PLESS Study-Incidence of Acute Urinary Retention and BPH-related surgery. A Teleconference Presentation. June 18, 1998. Houston, TX

232. Results of the PLESS Study-Incidence of Acute Urinary Retention and BPH-related surgery. A Teleconference Presentation. June 18, 1998. Houston, TX

233. Osteoporosis and Prostate Cancer-For Men and For Women. Presented to Memorial Business Women’s Association. July 14, 1998. Houston TX

234. Urology in the Year 2000. Presented to Shreveport Urological Symposium. Shreveport LA, October 15, 1998.

235. Evaluation and Treatment of Erectile Dysfunction. Presented to Primary
Care Symposium, Houston TX October 29, 1998.

236. External Marketing in the urology office. Presented to Urology seminar, Tampa FL Feb 8, 1999

236. Internal Marketing in the urology office. Presented to Urology seminar, Tampa FL Feb 8, 1999

237. The Importance of Exercise in the Elderly Patient. Presented as Keynote address to Senior Olympics Houston TX March 11, 1999

238. BPH: Differentail Diagnosis and Management. Presented to Urofocus Consultants’ Advisory Board Scientific Assembly. San Francisco. August 20, 1999

239 The Management of The Overactive Bladder: Presented to The Forum
August 26, 1999

240 Manangement of the Overactive Bladder: Presented to Baylor-Methodist Primary Physicans Chapter Meeting. Houston TX August 26, 1999

241. Management of Benign Prostatic Hyperplasia. Men’s Health Update Series. Houston TX Sept 30, 1999

242. Management of Erectile Dysfunction. Men’s Health Update Series. Houston Texas, Sept 30, 1999

243. Management of Benign Prostatic Hyperplasia-the Issue of Uroselectivity of alpha adrenergic blocking agents. Presented to Urologic Seminar, Overland Park KS October 9, 1999

243. Prevention and Treatment of Prostate Cancer. Presented to Men’s Helath Symposium. New Hope Lutheran Church. Missouri City TX Oct 17, 1999

244. Early Detection and Treatment of Prostate Cancer. Staff Seminar. Memorial Hermann Spring Shadows Pines. Houston TX Oc 20, 1999

245. Your Health Is Within Your Own Control. Keynote Address for opening of Memorial Hermann Houston Baptist University Wellness Center. Houston Texas October 25, 1999

246. Men’s Health Seminar Part II BPH and Erectile Dysfunction. Seminar in Houston Texas. November 4, 1999

247. Management of Complicated Urinary Infections. Presented to Primary Care/Urology Conference. Houston Texas, December 1, 1999

248. Management of Erectile Dysfunction for the Cardiac Patient. Presented to Cardiology Seminar. Houston Texas, December 4, 1999

249. Management of Erectile Dysfunction. Presented to Cardiology Seminar. Houston Texas, February 29, 2000

250. Evaluation and Management of Erectile Dysfunction. Presented to University of Texas Conference. College Station Texas, Feb 16, 2000

251. Experience with the Harmonic Scalpel In Radical Prostatectomy. Presented to Academia Peruana Conference. Lima Peru. March 7, 2000

252. Influence Sling Procedure in the Management of Stress Incontinence.
Presented to Academia Peruana Conference. Lima Peru. March 7, 2000

253. Current Issues and Reported Findings from the National Survey on BPH
Presented to Family Practice Symposium. Houston TX May 11, 2000

254. Management of Overactive Bladder. Presented to Primary Care Symposium. Conroe TX June 16,2000

255. The Importance of Communication in Dealing with Research Subjects. Presented to Houston Chapter of Clinical Research Associates. June 27, 2000.

256. Kenote Address: Physician-Patient Communication; Making the Most Out of Your Physician Visit. Presented to The Wellness Center. Houston TX. September 12,2000

257. Overactive Bladder and Interstitial Cystitis. Presented to Ob/Gyn Symposium, Houston Tx September 21, 2000

258. Prostate Cancer-Prevention, Early Detection and Treatment. Presented to Over 55 Symposium. Houston TX September 26, 2000

259. Erectile Dysfunction in the Era of Sildenafil. Presented to Bexar County Psychiatric Seminar. San Antonion TX Oct 4, 2000

260. Erectile Dysfunction in the Primary Care Setting. Presented to Houston Primary Care Physician Conference. October 12, 2000

261. Finasteride in the Management of BPH-presented to multispecialty symposium. Beaumont TX Oct 24, 2000

262. Finasteride in the Prevention of BPH Sequelae. Presented to Primary Care Symposium Houston TX October 25, 2000

263. New Paradigms in the Management of Porstate Disease. Presented to Urologic Conference, Albuquerque NM Oct 25, 2000

264. Management of Overactive Bladder. Presented to Primary Care Symposium Lafayette LA October 27. 2000

265. Bladder, Bladder What’s the Matter? Presented to Women’s Annual Helath Symposium Warwick Hotel, Houston TX October 28, 2000

266. Overactive Bladder-Evaluation and Case Studies. Presented to Primary Care Symposium. Houston TX October 28,2000

267. Evaluation and Management of Erectile Dysfunction. Presented to Neuro-psyciatric seminar, McAllen Medical Center. McAllen Texas, November 4, 2000

268. Evaluation and Management of Erectile Dysfunction. Presented to Texas Academy of Family Practice. Houston TX January 10, 2001

269. Evaluation and Management of Overactive Baldder. Presented to Texas Academy of Family Practice. Austin TX January 22, 2001

270. Prevention and Management of BPH-New Options. Presented to Urological Seminar. Lafayette LA Jan 29, 2001

271. Evaluation and Management of Overactive Baldder.Presented to Primary Care Symposium. Houston TX January 31, 2001

272. Evaluation and Management of Overactive Baldder.Presented to Primary Care Symposium. McAllen TX February1, 2001

273. Evaluation and Management of Overactive Baldder.Presented to Gynecology Symposium. McAllen TX February1, 2001

274. Evaluation and Treatment of Erectile Dysfunction. Presented to Internal Medicine Seminar. Houston TX February 6, 2001

275. Management of Urological Complications of Diabetes. Presented to Diabetes Quarterly Update Seminar. Houston TX Feb 10, 2001

276. Evaluation and Management of Overactive Bladder.Presented to Texas Acadmey of Family Practice Symposium. Austin TX February20, 2001

277. Evaluation and Management of Overactive Bladder.Presented to Internal Medicine Soutwest Symposium. Houston TX February 15, 2001

278. The Use of Cox-2 Inhibitors in Urology. Presented to Austin Academy of Urology. Austin TX Feb 21, 2001

279. Management of Overactive Bladder. Presented to Primary Care Symposium. ElPaso TX March 8, 2001

280. Management of Incontinece and Impotence-Newer Options. Presented to Primary Care/Gyn Symposium. McAllen TX March 15, 2001

281. Prevention, Prostatitis, and Pain. Presented to Urology Seminary. Lake Charles LA March 19, 2001

282. Prevention, Prostatitis, and Pain. Presented to Urology Seminary. Waco TX March 21, 2001

283. Prevention and Early Detection-BPH and Prostate Cancer. Presented to Willis-Knighton Medical Center. Shreveport LA March 28, 2001

284. Use of Cox-2 Inhibitors in Urology. Presented to Department of Urology. Louisiana State University Medical School. Shreveport LA March 28, 2001

285. The Influence Sling Procedure in the Treatment of Female Stress Incontinence. Continuing Education Course. Hospital Central Militar. Mexico City Mexico, April 21, 2001

286. Visiting Professorship: Hospital Central Militar, Mexico City. Surgical Demonstration of Female Sling Procedures. Mexico April 21, 2001

287. Evaluation and Management of Erectile Dysfunction. Grand Rounds Presentation-Department of Medicine, St. Jospeh’s Hospital. Houston TX May 1, 2001

288. Sildenafil in the Management of Erectile Dysfunction. Presented to Primary Care Roundtable. College Station TX May 3, 2001

289. Prevention, Prostatitis and Pain. Presented to: Primary Care Symposium Detroit MI, May 9, 2001

290. Prevention, Prostatitis and Pain. Presented to: Grand Rounds, Bottsford Hospital, Lavonia MI, May 9, 2001

291. Prevention, Prostatitis and Pain. Presented to: Urology Regional Meeting Kansas City, MO, May10, 2001

292. Evaluation and Treatment of Erectile Dysfunction: Presented to Primary Care Symposium. Houston TX May 11, 2001

293. Erectile Dysfunction in the Primary Care Setting. Presented to 2001 Symposium, Dallas TX May 22, 2001

294. Evaluation and Management of Overactive Bladder. Presented to Baton Rouge Family Care Symposium, Baton Rouge LA May 23, 2001

295. Roundtable Presentation-Use of Oxybutinin XL in the Management of Urinary Incontinence. Houston TX May 31, 2001

296. Prevention of Diseases of the Prostate. Resident’s Symposium. LSU Medical School. Shreveport LA June 5, 2001

297. Evaluation and Management of Overactive Bladder. Presented to OB/GYN Lecture Series. St. Louis MO June 23, 2001

298. Use of COX-2 Inhibitors in Urology. Presented to Urological Symposium-The Woodlands. The Woodlands TX June 26, 2001

299. The Influence Sling in the Management of Stress Urinary Incontinence. Advances in Urological Care Seminar. Ft. Lauderdale FL June 27, 2001

300. Prevention, Prostatitis and Pain. Presented to: Urological Society of Columbus. Columbus OH, June 28, 2001

301. Prevention, Prostatitis and Pain. Presented to: Urological Society of Cincinnati, Cincinnati OH July 23, 2001

302. Management of Erectile Dysfunction and New Advances. Presented to Primary Care Seminar. Houston TX July 30, 2001

303. Management of Urinary Incontinence in the Aging Population. Presented to the Texas Academy of Family Practice, Annual Meeting. Houston TX August 3, 2001

304. Prevention, Prostatitis and Pain. Presented to: Urological Society of Lubbock Texas, and the Texas Urological Society. Lubbock TX August 10, 2001

305. Management of Erectile Dysfunction and New Advances. Presented to Primary Care Seminar. Houston TX August 16, 2001

306. The Influence Sling in the Management of Stress Urinary Incontinence. Advances in Urological Care Seminar. Chicago IL August 22, 2001

307. Advances in the Management of Interstitial Cystitis. Presented to SUNA chapter meeting. Houston TX August 29, 2001

308. Management of the Overactive Bladder. Presented to the Texas Academy of Family Physicians. Austin TX Sept 15, 2001

309. Erectile Dysfunction in the Primary Care Environment-Screening for Co-morbidities. Presented to Primary Care Conference. Fort Worth TX October 20, 2001

310. Advances in the Evaluation and Management of Overactive Bladder. Presented to Urology Advisors Meeting. Houston TX Oct 17, 2001

311. Advances in the Management of Erectile Dysfunction. CME Grand Rounds Lecture. Spring Branch Hospital Houston TX Oc 23, 2001

312. Evaluation and Treatment of Erectile Dysfunction. Presented to Fleishman Memorial Meeting. October 27, 2001

313. Use of Finasteride and Rofecoxib in the Urology Setting. Presented to Urology Seminar. Springfield MO, November 7, 2001

314. Management of Overactive Bladder. Presented to Urology Roundtable. Houston TX December 4, 2001

315. Prevention and Early Detection of Prostate Diseases. Presented to Grand Rounds. VA Hospital, Alexandria LA December 6, 2001

316. Management of Erectike Dysfunction. Presented to Family Practice Roundtable. Houston TX Feb 13, 2002

317. Choosing the Ideal Treatment for Overactive Bladder. Control Conference. Houston TX Feb 26, 2002

318. Choosing the Ideal Muscarinic Receptor Blocker in the Management of Overactive Bladder. SOTA Conference. March 2, 2002

319. Management of Overactive Bladder. Control Conference. San Antonio TX March 5, 2002

320. Choosing the Ideal Treatment for Overactive Bladder. Control Conference. Aistin TX Feb 26, 2002

321. Visiting Professorship, Hospital Edgardo Reglabiati Martin, Lima Peru Treatment of Male Stress Incontinence with the InFast Sling. March 13, 2002

322. Visiting Professorship, Hospital Edgardo Reglabiati Martin, Lima Peru Treatment of Female Stress Incontinence with the Influence Sling. March 13, 2002

323. Visiting Professorship, Hospital Edgardo Reglabiati Martin, Lima Peru Treatment of Female Stress Incontinence with the SPARC Sling. March 13, 2002

324. Surgical Management of Post-Prostatectomy Incontinence. Presented to Academia Peruana Cirugia. Lima Peru, March 12, 2002

325. Use of Phosphodiesterase Inhibitors in the Treatment of Erectile Dysfunction. Presented to ED Primary Care Conference. Houston TX March 19, 2002

326. Ideal Pharmaceutical Management of Overacrive Bladder. Presented to Control Panel. Albuquerque NM, April 16, 2002

328. Ideal Pharmaceutical Management of Overacrive Bladder. Presented to Control Panel. Shreveport LA, April 23, 2002

329. Management of Erectile Dsyfunction in the Cardiac Patient. Presented to Cardiology Seminar. Houston TX June 7, 2002

330. The Physiology of Muscarinic Receptors in the Human Bladder. Presented to State-of-the-Art Lecture Series. Atlanta GA. June 22, 2002

331. Management of Overactive Bladder. Presented to Urological Nurses Symposium. Houston TX July 22, 2002

332. The Physiology of Muscarinic Receptors in the Human Bladder. Presented to State-of-the-Art Lecture Series. Philadelphia, MS August 24,2002

333. 5-alpha Reductase inhibition in the Management of Men with Symptomatic BPH. Presented to Southamptom Medical Clinic Monthly Seminar. Houston TX Aug 28, 2002

334. The Physiology of Muscarinic Receptors in the Human Bladder. Presented to State-of-the-Art Lecture Series. Philadelphia, MS Dallas TX September 14,2002

335. Management of Men and Women with Urinary Incontinence. Presented to
Women and Health Symposium. Houston Tx September 21, 2002

335. Evaluation and Treatment of the Overactive Bladder. Presented to Primary Care Symposium. Houston TX October 3, 2002

336. The Physiology of Muscarinic Receptors in the Human Bladder. Presented to State-of-the-Art Lecture Series. Houston TX ,October 5, 2002

337. The Physiology of Muscarinic Receptors in the Human Bladder. Presented to State-of-the-Art Lecture Series. Vero Beach FL October 12, 2002

338. Urological Consequences of Diabetes, their Evaluation and Management. Presented to Quarterly Diabetes Focus Seminar. Memorial City Hospital
Houston TX November 9, 2002

339. Tolterodine IR vs. Tolterodine LA in the Management of Overactive Bladder. Presented to Urological Seminar. Lake Charles LA. December 5, 2002

340. Proper Screening for Male Health Issues. Presented to the Windsor Club. Houston TX February 27, 2003

341. HIPAA and other related management issues for the urology practice. Presented to Baylor College of Medicine, Department of Urology, annual urology prosthetics seminar. Houston TX Feb 28, 2003

342. Evaluation and Management of the Overactive Bladder Patient. Presented to primary care seminar. Houston TX March 6, 2003

343. The role of muscarinic receptor blockers in the treatment of overactive bladder. A teleconference. March 18, 2003

344. The role of muscarinic receptor blockers in the treatment of overactive bladder. A teleconference. March 31, 2003

345. The role of muscarinic receptor blockers in the treatment of overactive bladder. A CME teleconference. April 7, 2003

346. Evaluation and Management of Erectile Dysfunction. Presented to combined primary care-Urology seminar, Beaumont, TX April 10. 2003

347. The role of muscarinic receptor blockers in the treatment of overactive bladder. A CME teleconference. April 7, 2003

348. The role of muscarinic receptor blockers in the treatment of overactive bladder. A CME teleconference. April 7, 2003

349. The role of oral agents in the management of erectile dysfunction. Presented to primary care seminar, Kingwood TX April 24, 2003

350. Evaluation and Management of Erec tile Dysfunction in the primary care setting. A CME teleconference. April 28, 2003

351. The role of 5 alpha-reductase inhibitors in the Management of Men with BPH. Presented to Educational Seminar, Kelsey-Seybold Clinic. Houston Tx. May 16, 2003

352. Evaluation and Management of Erec tile Dysfunction in the primary care setting. A CME teleconference. May 8, 2003

353. Evaluation and Management of Erec tile Dysfunction in the primary care setting. A CME teleconference. May 19, 2003

354. The role of 5 alpha-reductase inhibitors in the Management of Men with BPH Presented to Primary Care symposium. Houston TX May 22, 2003

355. Evaluation and Management of Erec tile Dysfunction in the primary care setting. A CME teleconference. May 29, 2003

356. The role of 5 alpha-reductase inhibitors in the Management of Men with BPH Presented to Hillcroft Medical Clinic Educational Symposium. Houston TX June 17, 2003

357. Present Evaluation and Treatment of Adults with Overactive Bladder syndrome. Presented to combine urology-primary care Symposium. Houston TX June 26, 2003

358. The role of 5 alpha-reductase inhibitors in the Management of Men with BPH Presented to Primary Care symposium. Houston TX July 2, 2003

359. The role of 5 alpha-reductase inhibitors in the Management of Men with BPH Presented to Primary Care symposium. Houston TX July 7, 2003

360. Evaluation and Management of Erec tile Dysfunction in the primary care setting. A CME teleconference. July 8, 2003

361. The role of 5 alpha-reductase inhibitors in the Management of Men with BPH Presented to Primary Care symposium. Houston TX July 15, 2003

362. Moderator: Introduction of a New PDE-5 Inhibitor; tadalafil. New Data. Presented to Combined urology-internal medicine seminar. Houston Tx July 17, 2003

363. The role of muscarinic receptor blockers in the treatment of overactive bladder. A CME teleconference. July 16, 2003

364. The role of 5-alpha-reductase inhibition in the management of men with BPH. Presented to primary care conference, Houston TX July 23, 2003

365. The role of antimuscarinic receptor blockade in the management of overactive bladder. A CME teleconference. Houston TX August 4, 2003

366. The role of antimuscarinic receptor blockade in the management of overactive bladder. A CME teleconference. Houston TX August 6, 2003

367. The role of antimuscarinic receptor blockade in the management of overactive bladder. A CME teleconference. Houston TX August 11, 2003

368. The management of men with hypogonadism. Presented to a combined Urology-Primary Care symposium Houston TX August 12, 2003

369. Dutasteride Therapy in Men with BPH. Presented to Primary Care Symposium, Houston TX August 13, 2003

370. The role of antimuscarinic receptor blockade in the management of overactive bladder. A CME teleconference. Houston TX August 14, 2003

371. The Medical Management of Men With Erectile Dysfunction. Presented to primary care symposium, Houston TX August 19, 2003

372. Five-Alpha Reductase inhibition in the Management of Men with BPH. Presented to primary care seminar. Houston TX August 20, 2003

373. The role of antimuscarinic therapy in the management of overactive bladder. A CME teleconference, Houston TX August 21, 2003

374. Medical Management of Men with BPH. CME conference, West Houston Medical Center, Houston TX, August 22, 2003

375. Results of the ACET Trial. Presented to combined Medical-Ob-Gyn Conference. Lafayette LA, September 3, 2003

376. Preventive Medicine-What You and Your Physician Can Do. Presented to the Rotary Club of West Houston. Houston TX September 9, 2003

377. New Advances in the Management of Overactive Bladder. Presented to the Deparment of Urology, Wilford Hall Hospital, San Antonio TX, September 10, 2003

378. Medical and Surgical Management of the Overactive Bladder. Presented to Primary Care Symposium. San Antonio TX September 10, 2003

379. New Developments in the Management of Men with Erectile Dysfunction. Presented to Primary Care Symposium. Kingwood TX September 9, 2003

380. Recent Advances in Erectile Dysfunction and Overactive Bladder. Presented to Urology Conference, The Woodlands TX September 16, 2003

381. Recent Trials in the Use of Viagra-Erectile Dysfunction and Non-Sexual Uses. Presented to Primary Care/Texas A&M University Residents. Collete Station TX, September 25, 2003

382. New Therapies for Erectile Dysfunction. Presented to Urology Conference. Beaumont TX Sept 30, 2003

383. 5 alpha reductase inhibition in the Management of BPH. Presented to primary care conference, Houston TX October 1, 2003

384. Medical Management of Erectile Dysfunction. Presented to Primary Care Symposium. Fort Worth TX October 3, 2003

385. Vardenafil, a New PDE-5 Inhibitor in the Management of Erectile Dysfunction. Presented to combined Uro/PCP Conference, Houston TX October 7, 2003

386. Medical Managent of Erectile Dysfunction. New Horizons. Presented to Combined Uro/PCP conference. Jackson MS, October 8, 2003

387. Medical Managent of Erectile Dysfunction. New Horizons. Presented to Combined Uro/PCP conference. Waco TX, October 9, 2003

388. Vardenafil-a new PDE-5 inhibitor. Presented to Primary Care Symposium. Humble TX October 15, 2003

389. New Horizons in the use of Sildenafil. Non-Sexual Uses. Presented to Primary Care Symposium. Huntsville TX October 22, 2003

390. Tolterodine and Oxybutinin in the Management of Overactive Bladder. Presented to Primary Care Symposium. Houston TX October 23,l 2003

391. Tolterodine and Oxybutinin in the Management of Overactive Bladder. Presented to Primary Care Symposium. Green Bay WI October 28,2003

392. Tolterodine and Oxybutinin in the Management of Overactive Bladder. Presented to Primary Care Symposium. Milwaukee WI October 29,2003

393. Sildenafil, Sexual and Non-Sexual Uses in Medical Practice. Presented to Primary Care Symposium. Houston TX. November 4, 2003

394. Tolterodine and Oxybutinin in the Management of Overactive Bladder. Presented to Primary Care Symposium. Houston TX November 5,2003

395. Tolterodine and Oxybutinin in the Management of Overactive Bladder. Presented to Primary Care Symposium. Houston TX November 6,l 2003

396. Vardenafil-a new PDE-5 inhibitor. Presented to Primary Care Symposium. Houston TX,November 11 2003

397. New advances in the Treatment of Overactive Bladder; Surgical and Non-Surgical. Presented to primary care Symposium. College Station TX November 13, 2003

398. Choosing the Proper Therapy for BPH Patients. Presented to West Houston Primary Care Clinic. Houston TX November 18, 2003

399. Keynote Speech; “We Live in Interesting Times” Presented to Americn Society of Industrial Security. Houston TX. November 19, 2003


Click Here for a List of Dr. Mobley's Publications

More than 40 publications: Books, Journal Publications, Videos, Tapes, and textbook chapters are available by request.